A Community Health Intervention to Improve Lung Cancer Screening Uptake in Community Health Centers
Part of paid clinical trials in Springfield, Massachusetts.
- Sponsor
- Baystate Medical Center
- Study ID
- NCT07168629
- Status
- Recruiting
Conditions
- Lung Cancer
- Tobacco Use
Eligibility Criteria
- Sex
- ALL
- Age
- 50 Years - 80 Years
- Healthy Volunteers
- Accepted
Interventions
- Community health worker delivered outreach, shared decision-making, tobacco treatment, and navigation — BEHAVIORALThe CHW will perform: 1) patient outreach 2) patient-centered shared-decision making, 3) tobacco treatmnet counseling, and 4) navigation of logistical barriers
- Lay Navigator delivered outreach, shared decision-making, tobacco treatment, and navigation — BEHAVIORALThe lay navigator will perform: 1) patient outreach 2) patient-centered shared-decision making, 3) tobacco treatment counseling, and 4) navigation of logistical barriers
- Enhanced Usual Care — OTHERParticipants will receive educational materials about lung cancer screening and usual lung cancer screening care through their primary care provider.
Study Details
Lung cancer screening (LCS) can reduce lung cancer-related mortality, but screening uptake remains low among eligible individuals. The goal of this study is to partner with community stakeholders to develop and pilot test a multi-component navigator-delivered intervention targeting key barriers to lung cancer screening and tobacco treatment utilization. Participants are randomized to enhanced usual care, a community health worker (CHW)-delivered intervention, or the same intervention delivered by a trained lay navigator. The intervention includes patient outreach, patient-centered shared decision-making, tobacco treatment counseling, and assistance navigating logistical barriers to care. The proposed activities will lay the groundwork for a subsequent fully powered randomized clinical trial evaluating CHW- and lay navigator-delivered approaches to facilitate access to lung cancer screening and tobacco treatment.
Key Dates
- First listed
- Sep 11, 2025
- Start date
- May 10, 2026
- Status verified
- Sep 2026
- Primary completion
- Feb 1, 2028
- Completion
- Aug 1, 2028
Study Design
- Enrollment
- 120 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- HEALTH_SERVICES_RESEARCH
Arms
- Active Comparator: Enhanced Usual CarePartcipants will receive educational materials about lung cancer screening
- Experimental: Community Health Worker-delivered InterventionParticipants will receive a four-part intervention delivered by a community health worker to improve lung cancer screening uptake. The intervention includes: 1) patient outreach, 2) patient-centered shared decision-making, 3) tobacco treatment counseling, and 4) navigation of logistical barriers to care.
- Experimental: Lay Navigator-delivered InterventionParticipants will receive the same four-part intervention delivered by a trained lay navigator to improve lung cancer screening uptake. The intervention includes: 1) patient outreach, 2) patient-centered shared decision-making, 3) tobacco treatment counseling, and 4) navigation of logistical barriers to care.
Primary Outcome Measure
Feasibility: Number of participants at each stage of the recruitment and retention cascade [ Time Frame: once a month until study trial ends, an average one year ]
Central Contacts
- Eduardo R Nunez, MD, MS1-855-794-5864
- Chisom Unegbu, BS
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Baystate Health | Springfield | Massachusetts | 01107 | - |
Find similar trials in Springfield, MA
Related Studies
- DNA Analysis of Blood and Tissue from Patients with Lung CancerRecruiting · Massachusetts General Hospital · Boston, Massachusetts
- Integrated Cancer Repository for Cancer ResearchRecruiting · University of Nebraska · Greenwood Village, Colorado
- Molecular and Genetic Analysis of Lung CancerRecruiting · Massachusetts General Hospital · Boston, Massachusetts
- APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid TumorsPHASE2 · Recruiting · Apollomics Inc. · Los Angeles, California